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Objective: Obesity is characterized by chronic subclinical inﬂammation, which is critical to endo-
thelial dysfunction. Weight loss, induced by lifestyle interventions, is associated with a decline in
biomarkers of inﬂammation and endothelial dysfunction. There is little evidence that high dietary
calcium intake may reduce inﬂammation and improve endothelial function. The purpose of this
study was to evaluate the effects of weight loss from a high-calcium energy-reduced diet on
biomarkers of inﬂammation, ﬁbrinolysis, and endothelial function in obese individuals.
Methods: In this randomized clinical trial, we analyzed the data from 35 obese adults who lost at
least 3% of initial body weight, during a period of 16 wk of energy restriction (800 Kcal/d).
Individuals were randomized into the following dietary regimens: (1) a high calcium diet (HCD;
1200–1300 mg/d) or (2) a low-calcium diet (LCD; <500 mg/d).
Results: After 16 wk of intervention subjects on HCD compared with those on LCD exhibited greater
reduction in waist circumference and waist-to-hip ratio. Participants on HCD presented a signiﬁ-
cant reduction in all biomarkers of endothelial dysfunction evaluated in the study (intracellular
adhesion molecule-1, vascular cell adhesion molecule 1, and E-Selectin), whereas subjects on LCD
showed a signiﬁcant decrease in intracellular adhesion molecule-1 and E-Selectin. Biomarkers of
inﬂammation and ﬁbrinolysis were reduced in both diets, although without reaching statistical
signiﬁcance. The reduction in all markers of inﬂammation, ﬁbrinolysis, and endothelial dysfunction
was similar in both diets.
Conclusion: The ﬁndings of this study suggest that increased calcium intake during weight loss has
no beneﬁts with respect to biomarkers of inﬂammation, ﬁbrinolysis, and endothelial function.
 2013 Elsevier Inc. All rights reserved.Introduction
Obesity is becoming a global epidemic in both children and
adults [1]. Overwhelming evidence supports the role of obesity
in the pathogenesis and progression of cardiovascular disease
[2], a leading cause of mortality in Westernized societies [3].
Adipose tissue, once considered a simple energy warehouse,
is now regarded as an active endocrine and paracrine organ
that releases a large number of bioactive mediators (adipokines)
that inﬂuence not only body weight homeostasis but also
inﬂammation, coagulation, ﬁbrinolysis, insulin resistance, andagas Filho de Amparo a
. G. Torres).
ll rights reserved.atherosclerosis [3–5]. Most adipokines with proinﬂammatory
properties are overproduced with increasing adiposity, whereas
some adipokines with antiinﬂammatory or insulin-sensitizing
properties, like adiponectin, are decreased. This dysregulation of
adipokines production may promote obesity-linked metabolic
disorders and cardiovascular disease [5].
Obesity represents a disease state characterized by chronic
subclinical inﬂammation. In fact, inﬂammatory markers, such as
C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis
factor-a (TNF-a), monocyte-chemoattractant protein-1 (MCP-1),
and plasminogen activated inhibitor (PAI-1), are increased in
obese individuals compared with lean subjects [6,7]. Inﬂamma-
tory mechanisms are critical to all stages of cardiovascular
disease progression and play a causal role in vascular endothelial
dysfunction that represents a crucial early event in atheroscle-
rosis and subsequent coronary heart disease events [7]. Weight
loss, induced by lifestyle interventions, is associated with
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dysfunction [8–10].
Recent evidence indicates that a calcium-rich diet may affect
energy balance, with an antiobesity effect [11,12]. Some studies
have suggested that during energy restriction, a high dietary
calcium intake improves weight loss and/or abdominal adiposity
reduction in obese individual [13–16], which probably enhances
the effect of energy restriction on biomarkers of inﬂammation
and endothelial dysfunction.
A recent observational study [17] identiﬁed an inverse asso-
ciation between dairy products consumption and levels of
various inﬂammatory markers among healthy adults. Few
interventional studies investigated the effect of dietary calcium
on inﬂammation and endothelial function. The majority of these
studies were conducted without concomitant energy restriction
(and/or weight loss) and their results are conﬂicting [18–22].
Therefore, the purpose of this study was to evaluate the
effects of weight loss from a high-calcium energy-reduced diet
on biomarkers of inﬂammatory stress, ﬁbrinolysis, and endo-
thelial function in obese individuals.
Materials and methods
Study design
This randomized, controlled clinical trial was conducted at the Laboratory of
Clinical and Experimental Pathophysiology, CLINEX, located at Pedro Ernesto
University Hospital, Rio de Janeiro State University.
Potential participants were recruited at the Department of Plastic Surgery,
among candidates for lipoplasty, and underwent initial eligibility screening by
registered dieticians. Subjects were assessed during a 2-wk run-in period to
evaluate their baseline diet and clinical status, after which a 16-wk intervention
period followed. The weight and physical activity of the eligible individuals were
stable, with no more than a 3-kg weight variation over the preceding 12 wk and
no recent change in exercise frequency or intensity. Using a computer-generated
randomization with the software STATA version 10.0 (StataCorp, College Station,
TX, USA), we randomized participants into a high-calcium diet (HCD) or a low-
calcium diet (LCD). We used block randomization to balance the size of HCD
and LCD groups.
Participants in both groups received individual instruction from the study
dietician, who provided nutritional assessment at baseline (week 0) and weeks 4,
8, 12, and 16. The development and reinforcement of strategies for continued
success were made at the same time points. Anthropometric parameters and
blood pressure levels were measured at baseline and at weeks 4, 8, 12, and 16.
Fasting plasma levels of circulating glucose, insulin, leptin, calcium, parathor-
mone (PTH), 1,25-dihydroxyvitamin D [1,25(OH)2D], lipid proﬁle, highly sensitive
CRP (hs-CRP), TNF-a, intracellular adhesion molecule 1 (ICAM-1), vascular cell
adhesion molecule 1 (VCAM-1), E-Selectin, and PAI-1 were evaluated at baseline
and at week 16. Blood samples were collect between 8 and 10 A.M. after an
overnight fast (12 h). Participants were asked to collect 24-h urine at baseline and
at week 16. Urinalysis was performed for calcium and creatinine.
Approval for the study was obtained from the Ethics Committee of Pedro
Ernesto University Hospital. All participants gave written informed consent. The
procedures followed in this study were in accordance with institutional
guidelines.
Subjects
Subjects were initially screened according to the following criteria: age
between 20 and 60 y, body mass index (BMI) between 30.0 and 34.9 kg/m2, and
a low habitual dietary calcium intake (<500 mg/d). The exclusion criteria
included the following: following special diets (i.e., vegetarian); intolerance to
lactose; use of medications affecting the metabolism, such as metformin, insulin,
diuretics, statins, and b-blockers; current calcium supplementation or use of any
medication known to interfere with calcium metabolism and body weight.
Individuals with eating disorders, major depression, or a medical history of drug
addictionwere also excluded. In addition, those with any metabolic disease, such
as diabetes mellitus or hypothyroidism, or chronic diseases severely affecting the
cardiovascular, gastrointestinal, and renal systems were also excluded. Pregnant
or lactating women were not allowed into the study.
Of the 198 individuals initially screened, 67 entered the run-in period.
Seventeen individuals did not complete this phase and were not enrolled in
the study. During the run-in period, potential participants were submitted todietary, anthropometric, and biochemical evaluation. Fourteen subjects (21%)
failed to complete the run-in period because (1) their calcium intake was more
than 500 mg/d (n ¼ 6); (2) the changes in body weight during the period
resulted in BMI values less than 30 or more than 35 kg/m2 (n ¼ 7); and (3) the
plasma glucose levels were maintained at values more than 126 mg/dL (n ¼ 1).
After completing the run-in period, participants were then randomized to the
following outpatient dietary regimens: (1) a HCD [1200–1300 mg/d, supple-
mented with non-fat powdered milk (60 g⁄d)] or (2) a LCD (<500 mg/d)
(Fig. 1). Both groups were instructed to follow a calorie-restricted regimen. All
calcium in both diets was derived from food sources. Thirty-nine subjects
(78%) completed the study, 19 in the HCD group and 20 in the LCD group. The
non-completers left the study because of scheduling conﬂicts, moving to
a distant area, illness or death of a relative, or loss of interest. In the present
analysis of data, to ensure that all subjects really experienced weight loss
during the study period, we included only the participants that lost at least 3%
of their initial body weight. Therefore, included in the ﬁnal analysis were 18
participants in HCD and 17 in LCD.
Amodest weight loss of 5% to 15% of initial body weight over a period of 6 mo
is considered realistic and of proven health beneﬁt [23], so we adopted a cutoff
point of 3% of weight loss, because the duration of the present study was 16 wk
(w4 mo).
Diets
The dietary assessments during the run-in period used a 3-d food record,
covering two weekdays and one weekend day, to estimate current calcium
consumption. During the intervention phase, the food records were reviewed
and clariﬁed in an interview with a registered dietician every 4 wk to assess
dietary adherence. Nutrient analysis of the 3-d food record was performed
using the software NutWin (S~ao Paulo Federal University, UNIFESP, S~ao Paulo,
Brazil).
In both intervention arms, low- and high-calcium diets, energy intake was
formulated to correspond to an 800 kcal/d reduction in the baseline total daily
energy expenditure, calculated using the World Health Organization equations
[24]. Both diets were structured to provide comparable levels of macronutrients
and ﬁbers: w22% of calories from protein, w28% from fat, w50% from carbohy-
drate, andw19 g of ﬁbers per day. Participants in the HCD received 60 g/d of non-
fat powdered milk. Reported total energy, percentage of energy from protein, fat,
and carbohydrate, and ﬁber content were similar in both diets (Table 1). Calcium
intake in HCD and LCD was 1245.6  20.3 and 456.7  15.3 mg/d, respectively
(P < 0.001) (Table 1).
Subjects were encouraged to use a meal plan based on their calorie intake
and an exchange list of nutrients. Participants were supplied with an analog
kitchen scale to assist in accurately measuring their food portions. Neither
subjects nor dieticians were blinded to the assigned diet.
Anthropometric measurements
Height, weight, and waist and hip circumferences were measured between
8 and 10 A.M. after a 12-h fast. Height was obtained using a stadiometer and
weight was measured with a Fillizola calibrated scale, accurate to 0.1 kg, after
participants, wearing a hospital gown, attempted to empty their bladder. BMI
was calculated using the standard equation (kg/m2). Waist circumference was
measured in the standing position, midway between the lower margin of the last
rib and the iliac crest. The measurements were taken at mid exhalation. Hip
circumference was measured at the widest point of the hip/buttocks area with
the measuring tape parallel to the ﬂoor. Waist-to-hip ratio was determined by
dividing waist circumference by hip circumference.
Body fat was estimated using an equation, based on skinfold thickness, which
was validated using a four-compartment model as the method of reference [25].
This equation includes the sum of the triceps, subscapular, suprailiac, and mid-
thigh skinfold thicknesses. These skinfold thicknesses were measured on the left
side of the body, using a Lange skinfold caliper (Beta Technology, Santa Cruz,
CA,USA), according to standard techniques [26].
The anthropometric measurements were taken twice and mean values were
used in all analyses.
Laboratorial parameters
Plasma samples were stored at 80C. Total cholesterol, high-density lipo-
protein cholesterol, and triglyceride concentrations were measured at the
hospital clinical laboratories using an automated analyzer. Low-density lipo-
protein cholesterol was calculated using the Friedewald formula [27] when
triglycerides did not exceed 400 mg/dL. Radioimmunoassay was used to deter-
mine plasma leptin and insulin levels (Linco Research, St Charles, MO, USA).
Fasting plasma glucose was determined by the use of the glucose oxidase
method. The insulin resistance status was assessed by the use of homeostasis
model assessment of insulin resistance (HOMA-IR) index [28]. The value of
Assessed for eligibility
n = 198
Week 0
High-calcium diet
n = 25
2-week run-in period
n = 67
Randomization
n = 50
Excluded (n = 131)
Not meeting the inclusion criteria
Excluded (n = 17)
- Not meeting the inclusion criteria (n = 14)
- Lack of interest (n = 3)
3 Dropouts
2 Personal reasons
1 Lack of interest 
Week 4
High-calcium diet
n = 22
2 Dropouts
2 Personal reasons 
1 Dropout
1 Personal reasons
1 Dropout
1 Lack of interest 
2 Dropouts
2 Personal reasons 
2 Dropouts
2 Personal reasons 
Week 8
High-calcium diet
n = 21
Week 12
High-calcium diet
n = 21
Week 16
High-calcium diet
19 participants completed the 
study and 18 were included in 
the analysis (lost at least 3% 
of initial body weight)
Week 16
Low-calcium diet
20 participants completed the 
study and 17  were included 
in the analysis (lost at least
3% of initial body weight)
Week 0
Low-calcium diet
n = 25
Week 4
Low-calcium diet
n = 23
Week 8
Low-calcium diet
n = 22
Week 12
Low-calcium diet
n = 20
Fig. 1. Flow diagram of the study.
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Diasorin SpA (Saluggia, Vercelli, Italy). Plasma PTH intact molecule was assessed
by electrochemiluminescence (Roche Diagnostics GmbH, Mannheim, Germany).
Serum and urinary calcium were determined by colorimetry. Urinary creatinine
was assessed by kinetic method. Highly sensitive CRP was determined by
turbidimetry using a commercial kit (Biosystems, Barcelona, Spain). Plasma
levels of TNF-a were determined by enzyme immunometric method using
commercial kits (Assay Designs, Ann Arbor, MI, USA). The values of ICAM-1,
VCAM-1, E-Selectin, and PAI-1 were determined by luminex xMAP method
using a commercial kit of multiple dosing (EMD Millipore Corporation, Billerica,
MA, USA).Table 1
Nutrient composition of reported intake during the study
Nutrient High-calcium
diet (n ¼ 18)
Low-calcium
diet (n ¼ 17)
P
Energy (Kcal/d) 1719.6  45.4 1698.1  51.3 0.63
Protein (% energy) 21.7  0.5 21.2  0.6 0.30
Fat (% energy) 28.4  0.6 28.2  0.7 0.54
Carbohydrate (% energy) 49.9  0.5 50.7  0.6 0.15
Fiber (g/d) 15.6  0.4 17.2  0.5 0.33
Calcium (mg/d) 1245.6  20.3 456.7  15.3 <0.001
Data are mean  SEM.Blood pressure
Blood pressure was recorded using a calibrated Dinamap 1846 Critikon
automated sphygmomanometer (Critikon, Tampa, FL, USA), after a resting period
of at least 10 min in the sitting position. An appropriate arm cuff was used. Arm
position was adjusted so that the cuff was at the level of the right atrium. Blood
pressure was measured on the dominant arm, every 3 min for 15 min, at
a constant temperature of 22–24C. The ﬁrst value was discarded, and the mean
of the last four readings was used in the analysis.Statistical methods
Mean values and standard errors were used to summarize quantitative
variables. Normality was tested by using the Shapiro-Wilk normality test.
Skewed data (triglycerides, insulin, leptin, PTH, HOMA-IR, hs-CRP, PAI-1, ICAM-1,
and E-selectin) were log transformed to improve normality. A t test for inde-
pendent samples was used to assess the differences of variables between the two
groups at baseline. For biochemical variables (evaluated at week 0 and week 16),
intra- and intergroup differences were assessed by a t test. For anthropometric
parameters and blood pressure levels (that were evaluated at weeks 0, 4, 8, 12,
and 16), we used repeated measures ANOVA to evaluate intra- and intergroup
differences. Multiple linear regression analysis was used to adjust for con-
founding factors (age, gender, and baseline values of each variable). Categorical
variables were compared by c2 test. A P < 0.05 was considered signiﬁcant. All
Table 2
Baseline characteristics of study subjects
Characteristic High-calcium
diet (n ¼ 18)
Low-calcium
diet (n ¼ 17)
P
Age (y) 40.5  2.4 44.1  2.6 0.24
Sex (female/male) 17/1 15/2 0.51
Body weight (kg) 83.3  2.6 81.6  2.6 0.62
Body mass index (kg/m2) 32.2  0.3 32.1  0.4 0.83
Body fat (%) 43.2  0.8 42.6  1.2 0.67
Body fat (kg) 35.9  1.0 34.5  1.1 0.35
Waist circumference (cm) 98.9  1.2 98.7  1.5 0.94
Hip circumference (cm) 112.9  1.5 111.1  1.8 0.47
Waist-to-hip ratio 0.88  0.01 0.89  0.02 0.52
Glucose (mg/dL) 99.5  2.1 97.6  3.5 0.65
Insulin (mU/mL) 21.2  1.5 23.1  2.8 0.55
HOMA-IR 5.2  0.3 5.8  0.8 0.50
Total cholesterol (mg/dL) 208.0  9.2 208.1  12.3 0.99
HDL-cholesterol (mg/dL) 53.2  3.4 49.2  1.6 0.29
LDL-cholesterol (mg/dL) 124.6  7.7 128.9  9.8 0.73
Triglycerides (mg/dL) 157.6  21.7 147.6  15.8 0.71
Leptin (ng/mL) 30.0  3.9 27.3  3.1 0.59
Total serum calcium (mg/dL) 9.4  0.1 9.4  0.1 0.58
Ionized serum calcium (mg/dL) 5.3  0.1 5.4  0.1 0.09
24-h urine calcium/creatinine (mg/mg) 0.13  0.02 0.12  0.02 0.33
Parathormone (pg/mL) 34.1  3.3 30.0  2.5 0.34
1.25(OH)2vit D (pg/mL) 79.7  3.5 68.9  3.9 0.06
hs-CRP (mg/L) 0.26  0.02 0.36  0.05 0.11
Tumor necrosis factor-a (pg/mL) 3.1  0.6 4.3  0.9 0.26
PAI- 1 (pg/dL) 106.2  9.3 104.8  16.3 0.94
ICAM-1 (ng/mL) 146.0  25.1 193.8  44.0 0.33
VCAM-1 (ng/mL) 930.3  43.7 1016.4  97.3 0.42
E-Selectin (ng/mL) 31.2  3.1 34.1  3.4 0.57
Systolic blood pressure (mmHg) 118.1  2.0 114.1  2.0 0.20
Diastolic blood pressure (mmHg) 76.6  2.1 72.1  1.9 0.11
Mean blood pressure (mmHg) 90.5  2.1 86.1  1.8 0.12
HDL, high-density lipoprotein; hs-CRP, high sensible C-reactive protein; ICAM-1,
intracellular adhesion molecule 1; LDL, low-density lipoprotein; PAI-1, plas-
minogen activator inhibitor 1; VCAM-1, vascular cell adhesion molecule 1.
Data are mean  SEM.
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College Station, TX, USA).
Results
Both treatment groups were comparable in all characteristics
at baseline (Table 2). As expected from the experimental design,
there was a signiﬁcant reduction in all anthropometric param-
eters of the participants allocated in both HCD and LCD, because
of the energy deﬁcit of 800 kcal/d (Table 3). Subjects in HCDTable 3
Anthropometric parameters and blood pressure levels at baseline (week 0) and at the
High-calcium diet (HCD) (n ¼ 18)
Week 0 Week 16 D P
Body weight (kg) 83.3  2.6 78.0  2.1 5.3  0.9 <
Body mass index (kg/m2) 32.2  0.3 30.1  0.4 2.0  0.3 <
Body fat (%) 43.2  0.8 40.4  0.8 2.9  0.4 <
Body fat (kg) 35.9  1.0 31.4  1.0 4.5  0.7 <
Waist circumference (cm) 98.9  1.2 90.8  1.3 8.1  1.3 <
Waist-to-hip ratio 0.88  0.01 0.84  0.01 0.04  0.0 <
Systolic blood pressure (mmHg) 118.4  2.6 109.4  2.6 9.0  1.6 <
Diastolic blood pressure (mmHg) 76.2  2.0 69.3  2.2 7.3  1.2 <
Mean blood pressure (mmHg) 90.5  2.1 82.7  2.3 7.8  1.1 <
Data are mean  SEM. D ¼ week 16  week 0.
* P value refers to changes during the study, considering the values at weeks 0, 4,
y P value refers to changes during the study, considering the values at weeks 0, 4,
z HCD versus LCD by repeated measures ANOVA.
x HCD versus LCD diet by repeated measures ANOVA adjusted for age, gender, anddemonstrated a signiﬁcantly greater reduction in waist circum-
ference and waist-to-hip ratio when compared with those in the
LCD (Table 3 and Fig. 2). Regarding body weight and body fat, the
differences between groups were not statistically signiﬁcant
(Table 3 and Fig. 2). The reduction in anthropometric measures
presented a continuous trend during all the study period (Fig. 2).
Approximately 85% of weight loss corresponded to estimated fat
loss in both groups.
Serum concentration of glucose, insulin, HOMA-IR, total
cholesterol, triglycerides, and leptin decreased signiﬁcantly in
both groups (Table 4). There was no signiﬁcant difference
between groups in relation to the modiﬁcations in metabolic
proﬁle during the study period (Table 4). Serum levels of PTH and
1,25(OH)2vitD were signiﬁcantly reduced after 16 wk of inter-
vention only in the HCD. Comparisons of changes in PTH values
between groups showed a signiﬁcantly greater reduction in this
variable in the HCD (Table 4). Systolic, diastolic, and mean blood
pressure presented a signiﬁcant reduction in both groups.
Participants in HCD compared to subjects in LCD presented
a signiﬁcantly higher reduction in blood pressure (Table 3 and
Fig. 2).
Serum levels of hs-CRP and TNF-a decreased from baseline to
the end of the study (week 16) in both diets. However, the
reduction in these biomarkers of inﬂammation was not statisti-
cally signiﬁcant in both groups (Fig. 3). The comparative analysis
of the changes in these parameters between HCD and LCD
showed no statistical signiﬁcance for hs-CRP (P ¼ 0.20) and for
TNF-a (P ¼ 0.61), even after adjusting for confounding factors
(age, gender, and baseline values of each variable) (P > 0.05).
PAI-1 was also reduced during the study period without
reaching statistical signiﬁcance in HCD and LCD, although there
was a trend to be statistically signiﬁcant in both groups (Fig. 3).
Participants in HCD and in LCD showed a similar reduction in this
biomarker of ﬁbrinolysis (P ¼ 0.97), even after adjusting for
confounding factors (P > 0.05).
HCD subjects presented a signiﬁcant reduction in serum
levels of all the studied adhesion molecules (ICAM-1, VCAM-1,
and E-Selectin), whereas participants in LCD presented a signiﬁ-
cant decrease only in ICAM-1 and E-Selectin (Fig. 3). The
comparative analysis between HCD and LCD showed that the
reduction in these biomarkers of endothelial dysfunction was
similar in both groups: ICAM-1 (P ¼ 0.65), VCAM-1 (P ¼ 0.47),
and E-Selectin (P ¼ 0.99). The decrease in these biomarkers
remained similar in both diets even after controlling for
confounders (P > 0.05).end of the study (week 16) in the different groups of calcium intake
Low-calcium diet (LCD) (n ¼ 17) Pz Px
* Week 0 Week 16 D Py
0.001 81.6  2.6 77.2  2.8 4.4  0.6 <0.001 0.42 0.60
0.001 32.1  0.4 30.3  0.5 1.8  0.3 <0.001 0.54 0.78
0.001 42.6  1.2 40.1  1.3 2.5  0.4 <0.001 0.60 0.66
0.001 34.5  1.1 30.8  1.4 3.7  0.5 <0.001 0.38 0.74
0.001 98.7  1.5 92.9  1.6 5.8  0.6 <0.001 0.04 0.04
0.001 0.89  0.02 0.86  0.02 0.03  0.01 <0.001 0.04 0.04
0.001 114.1  2.0 110.0  2.1 4.1  1.2 0.005 0.02 0.03
0.001 72.1  1.9 68.2  1.4 3.9  1.1 0.003 0.04 0.04
0.001 86.1  1.8 82.2  1.6 3.9  0.9 <0.001 0.01 0.02
8, 12, and 16 in HCD, and was estimated by repeated measures ANOVA.
8, 12, and 16 in LCD, and was estimated by repeated measures ANOVA.
baseline values of each variable.
W = Week, BP = blood pressure
*adjusted for age, gender and baseline values of each variable
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In the present clinical trial, based on a sample of obese indi-
viduals who lost at least 3% of initial bodyweight from an energy-
reduced diet (randomized to a HCD or a LCD), the main ﬁndings
were as follows: (1) a signiﬁcant reduction in all biomarkers of
endothelial dysfunction (ICAM-1, VCAM-1, and E-Selectin) in
HCD; (2) a signiﬁcant decrease in ICAM-1 and E-Selectin in LCD;
(3) biomarkers of inﬂammation and ﬁbrinolysis reduced in both
diets, although without reaching statistical signiﬁcance; (4) the
reduction in all biomarkers of inﬂammation, ﬁbrinolysis, and
endothelial dysfunction was similar in both diets.
In the present study, we selected only patients who really lost
weight, because our objective was to evaluate the effects of
a high-calcium intake, during weight loss, on inﬂammation,
ﬁbrinolysis, and endothelial function. Although it was not the
aim of the present study, participants in HCD compared to
subjects in LCD presented a signiﬁcantly higher decrease in
abdominal obesity and blood pressure.CRP is a hepatically derived inﬂammatory response marker
that increases up to 1000-fold in response to infection and tissue
destruction. Standard tests for PCR determine these highly
elevated CRP levels, but cannot adequately assess the normal
ranges of this protein. Highly sensitive CRP detects levels of CRP
within the normal range as well as higher levels. Observational
and epidemiological studies have suggested the potential
predictive role of hs-CRP in the prediction of cardiovascular
events [29,30].
Cross-sectional and interventional studies have shown that
hs-PCR is positively associatedwith adiposity parameters such as
BMI [31] and that weight loss in obese individuals reduces
signiﬁcantly the levels of this protein [8,9,32,33]. In a systematic
review [8] of lifestyle intervention studies, the mean weight
changewas –6.2 kg during amean period of 7.5 mo and themean
change in hs-CRP levels was –0.9 mg/L (range, –2.3 to 0.5 mg/L).
Heilbronn et al. [9] investigated the effects of weight loss in 83
obese women (mean BMI of 33.8 kg/m2 and mean CRP of 5.6
mg/L). Subjects were placed on very-low-fat, energy-restricted
Table 4
Metabolic variables at baseline (week 0) and at the end of the study (week 16) in the different groups of calcium intake
High-calcium diet (n ¼ 18) Low-calcium diet (n ¼ 17) Pz Px
Week 0 Week 16 D P* Week 0 Week 16 D Py
Glucose (mg/dL) 99.5  2.1 93.7  2.3 5.8  1.9 0.006 97.6  3.5 94.0  2.8 3.6  1.6 0.03 0.64 0.52
Insulin (mU/mL) 21.2  1.5 17.1  1.56 4.1  1.23 0.004 23.1  2.8 18.6  2.6 4.5  1.9 0.03 0.91 0.82
HOMA-IR 5.2  0.3 3.9  0.4 1.3  0.3 0.001 5.8  0.8 4.4  0.6 1.4  0.5 0.02 0.69 0.68
Total cholesterol (mg/dL) 208.0  9.2 191.2  9.6 16.8  5.0 0.004 208.1  12.3 192.5  9.9 15.6  5.2 0.008 0.87 0.71
HDL-cholesterol (mg/dL) 53.2  3.4 51.9  3.2 1.3  1.4 0.38 49.2  1.6 48.6  2.1 0.6  1.5 0.70 0.74 0.84
LDL-cholesterol (mg/dL) 124.6  7.7 117.1  8.4 7.4  4.7 0.13 128.9  9.8 120.3  8.0 8.6  4.6 0.08 0.87 0.89
Triglycerides (mg/dL) 157.6  21.7 114.1  0.2 43.4  12.2 0.003 147.6  15.8 117.6  11.6 29.9  7.6 0.001 0.54 0.46
Leptin (ng/mL) 30.0  3.9 23.0  3.5 7.0  2.2 0.006 27.3  3.1 22.8  4.0 4.5  2.3 0.006 0.45 0.57
Total serum Caþþ (mg/dL) 9.4  0.1 9.5  0.1 0.1  0.1 0.34 9.4  0.1 9.4  0.1 0.04  0.1 0.78y 0.26 0.32
Ionized serum Caþþ (mg/dL) 5.3  0.1 5.3  0.1 0.03  0.01 0.70 5.4  0.1 5.4  0.1 0.04  0.1 0.64y 0.54 0.58
24-h urine Caþþ/Creatinine (mg/mg) 0.13  0.02 0.16  0.02 0.03  0.02 0.12 0.12  0.02 0.12  0.02 0.00  0.01 0.92y 0.18 0.16
Parathormone (pg/mL) 34.1  3.3 29.7  2.9 4.4  1.3 0.004 30.0  2.5 31.6  2.4 1.6  2.4 0.50y 0.04 0.03
1.25(OH)2vit D (pg/mL) 79.7  3.5 68.9  3.7 10.8  5.3 0.04 68.9  4.0 68.4  4.1 0.5  5.1 0.49y 0.15 0.12
HDL, high-density lipoprotein; LDL, low-density lipoprotein; D ¼ week 16  week 0.
Data are mean  SEM.
* P value refers to differences between baseline and end of study (week 0 versus week 16) in HCD and was estimated by t test.
y P value refers to differences between baseline and end of study (week 0 versus week 16) in LCD and was estimated by t test.
z HCD versus LCD diet by t test.
x HCD versus LCD diet by t test adjusted for age, gender, and baseline values of each variable.
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and CRP was signiﬁcantly decreased by 26% (P < 0.001).
In the present study we did not observe a signiﬁcant reduc-
tion in hs-PCR levels in both groups. The possible explanations
for this lack of agreement between our results and the ﬁndings of
the literature are that, in comparisonwith the studies cited in the
above paragraph [8,9,32], (1) our participants in HCD and in LCD
presented lower baseline levels of BMI (32.2 and 32.1 kg/m2,
respectively) and hs-CPR (0.26 and 0.36 mg/L, respectively); and
(2) the magnitude of weight loss in HCD and LCD was also lower
(5.3 and 4.4 kg, respectively).
Participants in HCD and in LCD did not present a signiﬁcant
reduction in serum levels of TNF-a. This ﬁnding is also diver-
gent from what was observed in other studies, in which weight
loss was associated with a signiﬁcant decrease in TNF-a [10,
34]. The possible mechanisms responsible for this disagree-
ment with other studies are the same as were mentioned for
hs-PCR.
PAI-1 is the most important endogenous inhibitor of tissue
plasminogen activator and is a main determinant of ﬁbrinolytic
activity. There is now compelling evidence that obesity is asso-
ciated with elevated PAI-1 levels [35]. Weight loss is associated
with a signiﬁcant reduction in PAI-1, which is proportional to the
degree of weight loss [33,36]. We observed a decrease in PAI-1
levels with a trend to be statistically signiﬁcant in both groups.
The present study showed a signiﬁcant decrease in ICAM-1
and E-Selectin in both groups. However VCAM-1 was signiﬁ-
cantly reduced only in HCD. These ﬁndings are in agreement
with other studies that evaluated the effect of weight loss on
adhesion molecules and observed a signiﬁcant reduction in its
serum levels [10,33,36,37].
Our results demonstrated that the reduction in biomarkers of
inﬂammation (hs-CRP and TNF-a), ﬁbrinolysis (PAI-1), and
endothelial dysfunction (ICAM-1, VCAM-1, and E-Selectin) was
similar in HCD and LCD. Participants in HCD, compared to
subjects in LCD, although they presented a similar weight loss
during the study, had a greater decrease in abdominal obesity
and even so the reduction in these biomarkers was similar.
The comparison of our results (in relation to the effect of
a high calcium intake) with other studies is difﬁcult, because
of the small number of published studies evaluating the effectof dietary calcium on these biomarkers, and to the best of our
knowledge only one study was conducted during weight loss
[21]. In the former study, Zemel and Sun [21] performed an
evaluation of hs-CRP in archival samples from two previous
clinical trials conducted in obese individuals. Twenty-four weeks
of feeding a high-dairy eucaloric and hypocaloric diet resulted in
an 11% (P < 0.03) and 29% (P < 0.01) decrease in hs-CPR,
respectively (post- versus pretest), whereas there was no
signiﬁcant change in the low-dairy groups.
Although our study was conducted during weight loss, we
will compare our ﬁndings with studies during a eucaloric diet.
Recently, Stancliffe et al. [22] determined the early (7 d) and
sustained (4 and 12 wk) effects of adequate-dairy (3.5 servings/
d) compared with low-dairy (0.5 servings/d) weight-
maintenance diets in subjects with metabolic syndrome.
Inﬂammatory markers were suppressed with adequate-dairy
intake: at 12 wk TNF-a showed a 35% reduction (P ¼ 0.05), IL-6
21% reduction (P ¼ 0.02), and MCP-1 24% decrease (P ¼ 0.05).
Low-dairy diet exerted no effect on inﬂammatory markers.
Although diet had no effect on body weight, adequate-dairy diet
reduced waist-circumference and trunk fat (P < 0.01 for both).
Zemel et al. [18] evaluated the acute effects of a dairy-rich diet
on inﬂammatory stress in overweight and obese subjects in the
absence of adiposity changes. Twenty subjects (10 obese, 10
overweight) participated in a blinded, randomized, cross-over
study of dairy- compared with soy-supplemented eucaloric
diets. Inﬂammatory stress biomarkers were measured on days 0,
7, and 28 of each dietary period. The dairy-supplemented diet
resulted in lower inﬂammatory markers (TNF-a: 15%, P ¼ 0.002;
IL-6: 13%, P ¼ 0.01; MCP-1: 10%, P ¼ 0.0006) and increased
adiponectin (20%, P ¼ 0.002), whereas the soy-supplemented
diet exerted no signiﬁcant effect. These effects were evident by
day 7 of treatment and increased in magnitude at the end of the
28-d treatment periods.
On the other hand, two other interventional studies [19,20]
did not observe signiﬁcant changes in biomarkers of inﬂamma-
tion and of endothelial dysfunction. Wennersberg et al. [20]
evaluated 121 overweight subjects (n ¼ 121), with traits of the
metabolic syndrome, that were randomly assigned into milk or
control groups. The milk group was instructed to consume three
to ﬁve portions of dairy per day. The control group maintained
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Fig. 3. Mean levels of (A) highly sensible C-reactive protein (hs-CRP), (B) tumor necrosis factor-a (TNF-a), (C) plasminogen activated inhibitor (PAI-1), (D) intracellular
adhesion molecule 1 (ICAM-1), (E) vascular cell adhesion molecule 1 (VCAM-1), and (F) E-Selectin at baseline (week 0) and at the end of the study (week 16), according to
dietary intervention (n ¼ 35). P value was estimated by t test.
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admission and after 6 mo. There were no signiﬁcant differences
between changes in markers of inﬂammation and endothelial
function in the milk and the control groups. When the sexes
were analyzed separately, VCAM-1 decreased (P ¼ 0.001) in
women in the milk group. Van Meijl and Mensink [19] investi-
gated the effects of low-fat dairy consumption on inﬂammatory
markers and adhesion molecules in overweight and obese
subjects. Thirty-ﬁve subjects consumed, in a random order,
low-fat dairy products (500 mL low-fat milk and 150 g low-fat
yogurt) or carbohydrate-rich control products (600 mL fruit
juice and three fruit biscuits) daily for 8 wk. Plasma concentra-
tion of TNF-a was decreased (P ¼ 0.07) after the dairy diet
consumption. Low-fat dairy consumption did not affect other
markers of low-grade systemic inﬂammation (IL-6 and MCP-1)
and endothelial dysfunction (ICAM-1 and VCAM-1).
At present, there is no consensus about the effect of dietary
calcium on inﬂammation and endothelial function. However, the
lack of a positive effect of calcium in the present study may have
been inﬂuenced by the higher baseline levels (without statistical
signiﬁcance) of hs-CRP, TNF-a, ICAM-1, VCAM-1, and E-Selectin
in LCD.
Although in the present study we did not ﬁnd any effect of
higher dietary calcium on inﬂammatory biomarkers, the proposed
mechanism by which dietary calcium intake could modulate
inﬂammatory stress is probably mediated, in part, by the reduc-
tion in body fat. However, it has been shown that calcium may
have additional effects via suppression of 1,25(OH)2vitD. Elevated
serum levels of calcitriol, besides increasing intracellular calcium
concentration, appear to increase the production of reactive
oxygen species, throughmodulation of mitochondrial uncoupling.
These two mechanisms modulate the production and release of
cytokines [18,38].
There are several limitations to our study. First, although this
study was a randomized clinical trial, it was open-labeled.
Second, we consider this study exploratory, and additional
research with a longer period of intervention is therefore indi-
cated. Third, we cannot exclude that an additional bioactivity of
dairy products (i.e., non-calcium-mediated), such as that
resulting from the high concentration of leucine and of
angiotensin-converting enzyme inhibitors, contributed to the
proposed beneﬁts [39].
In conclusion, the ﬁndings of this study suggest that increased
calcium intake during weight loss has no beneﬁts beyond those
achieved with energy restriction on biomarkers of inﬂammation,
ﬁbrinolysis, and endothelial function. However, more studies are
necessary to evaluate this important issue.References
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